Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?
about
sameAs
The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?The Benefit and Safety of Aspirin for Primary Prevention of Ischemic Stroke: A Meta-Analysis of Randomized TrialsAntithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonistThe variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials.Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?Coronary stent thrombosis related to aspirin resistance: what are the underlying mechanisms?Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphismAspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patientsRecent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problemsAspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treStatins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trialAspirin resistance: Fact or fiction? A point of view.Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis.Cardiac thromboxane A2 receptor activation does not directly induce cardiomyocyte hypertrophy but does cause cell death that is prevented with gentamicin and 2-APB.A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass.The lack of aspirin resistance in patients with coronary artery diseaseAssessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart diseaseResistance to aspirin and clopidogrel therapy.A contemporary viewpoint on 'aspirin resistance'.Aspirin resistance.Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, prevents hypertensive vascular hypertrophy and fibrosis.Augmentation of U46619 induced human platelet aggregation by aspirin.Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus.Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease.Establishment of reference ranges and evaluation of in vitro concentration-dependent platelet inhibition by acetylsalicylic acid for multiple electrode impedance aggregometry in healthy dogs.Polymorphisms and high on-aspirin platelet reactivity after off-pump coronary artery bypass grafting.
P2860
Q24794673-40CB8E4A-040C-490E-94EB-3B66EE620960Q28066973-1A6E28FC-A913-46B5-8975-95BFB7DC54A9Q28167658-60E290E6-F124-424B-97A5-6EB2708CEF43Q28192919-7B847479-E1C3-446A-B3C3-CC36DC83E6D3Q28196511-168D46C9-FAAE-4763-9BD6-6063C7DF16BCQ28210440-ED9A6B52-3E38-4DDF-AAD9-CCCD34723D91Q28217995-F0F9033E-CBF7-4629-9FD1-1D43660AE545Q28218133-833F12A6-13BC-41BC-B5E1-7D90A08693BAQ28218351-DCE16EB2-DAFF-475C-B46D-E97A1CF76935Q28220363-1D057F21-9DAB-4589-B81C-C23FBDAB51ECQ28481709-BE7AA944-F545-43D6-9752-8EA2FF7A4A85Q34389630-B390DD76-E751-4B14-8642-BE1725E91801Q34996909-C7E2CEE7-6327-472E-90F8-82EB8325333DQ35527857-36A36309-FF29-4DFA-A507-B50AEEEEF169Q36374457-F012C373-45B0-4359-A247-6B2ECFC5370DQ36691432-923D7008-F835-4C8A-8A34-4C1A97E48B68Q37248584-A12D471E-1F90-40D8-9CFF-D400811FEB36Q37807524-06EB6636-1BD4-4C82-86C4-1F7A29EBC751Q37989558-ECCF4712-7E70-4157-8B01-1CE68C2E9FC0Q42641720-47487F83-1C6E-4B05-A179-C1F31396D20CQ45145010-A68B5A1F-8DB5-4000-84D7-617E1F7E68C0Q46113383-B1D1F20B-9787-457A-ACA0-F56258819898Q46879415-15EF2AC4-EEF8-4395-9213-7789EDBE62DEQ47385143-10597E6A-B746-438D-82D4-B58AA2B853A2Q48306826-80BECDA8-43D7-493C-99F5-41FC1F239F4FQ50979736-527FFE9D-7F73-45CE-B1A7-E01B15FF3377
P2860
Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Why are some individuals resis ...... n? Could it be thromboxane A2?
@ast
Why are some individuals resis ...... n? Could it be thromboxane A2?
@en
Why are some individuals resis ...... n? Could it be thromboxane A2?
@nl
type
label
Why are some individuals resis ...... n? Could it be thromboxane A2?
@ast
Why are some individuals resis ...... n? Could it be thromboxane A2?
@en
Why are some individuals resis ...... n? Could it be thromboxane A2?
@nl
prefLabel
Why are some individuals resis ...... n? Could it be thromboxane A2?
@ast
Why are some individuals resis ...... n? Could it be thromboxane A2?
@en
Why are some individuals resis ...... n? Could it be thromboxane A2?
@nl
P1433
P1476
Why are some individuals resis ...... n? Could it be thromboxane A2?
@en
P2093
Marc K Halushka
Perry V Halushka
P304
P356
10.1161/01.CIR.0000015422.86569.52
P407
P577
2002-04-09T00:00:00Z